Further developing drug compounds that interfere CSN6‐mediated HMGCS1 stabilization or inhibit HMGCS1 activity by small molecules can be further developed as a rational cancer therapy for CSN6‐overexpressing HCC. Here, HMGCS1 is linked to hepatocellular carcinoma.